PHILADELPHIA, PA — November 10, 2025 — Leads & Copy — Vittoria Biotherapeutics, Inc., a clinical-stage immunotherapy company, will present interim clinical data from its Phase 1 first-in-human study of VIPER-101 at the American Society of Hematology annual meeting, December 6 – 9, 2025, in Orlando, Florida. VIPER-101 is a CD5-modulated autologous CAR-T therapy for patients with relapsed or refractory (r/r) T-cell lymphoma (TCL).
The presentation will include details from the dose finding study (VIPER 101) of dual population autologous CD5 deleted anti-CD5 CAR T (Senza5 CART5) cells in Relapsed/Refractory T cell lymphomas.
Nicholas Siciliano, Ph.D., Chief Executive Officer of Vittoria Biotherapeutics, said that T-cell lymphoma has remained a challenging disease with limited therapeutic advances. He also stated that Vittoria’s interim clinical data provide evidence of the therapeutic benefits of their Senza5 platform technology. He added that the data demonstrate the potential of their CD5-targeted, dual-population CAR-T candidate to shift the treatment paradigm for patients living with T-cell lymphoma.
VIPER-101 is a gene-edited, autologous, dual-population cell therapy being evaluated as a potential treatment for patients with T cell lymphoma. It targets CD5, which is present on cancer cells in more than 85% of patients with T cell lymphoma and leverages the company’s proprietary Senza5 platform technology.
Senza5™ is a cell therapy engineering and manufacturing platform that combines genetic engineering and a five-day manufacturing process to maximize stemness, durability, and efficacy of cell therapies. It works by disabling the CD5 signaling pathway on engineered CAR T cells and bypassing CD5’s immunosuppressive effects to amplify the therapy’s antitumor activity.
Nicholas A. Siciliano, Ph.D., Chief Executive Officer of Vittoria Biotherapeutics, Inc. can be contacted at +1 215-600-1380.
Jason Braco, Ph.D. of LifeSci Communications can be reached at jbraco@lifescicomms.com or +1 646-876-4932.
Source: Vittoria Biotherapeutics
